This is required continuation round 2 in the same session.

Hard boundaries:
- Read-only clinical/medical delta review. Do not edit any file, start a service,
  access a real project/dictionary/provider, or read the other participant output.
- Runner-managed report path: `runs/conference/medical_monitoring_r4_d02_cm_contract_20260811/general_pi_qwen38_round2.md`. Return the report in your final response; do not write it with tools.

Initial read set:
- `reviews/medical_monitoring_r4_d02_cm_slice_contract_v1_20260811.md`
- `reviews/medical_monitoring_r4_risk_coverage_matrix_v1_20260810.md`

Do not restart the task or repeat the full reconnaissance. The draft is now
`v1.1-rc1 / REVISION_1_PENDING_DELTA_REVIEW`. Review only whether the current
text closes your own B1-B4 and N1-N8 findings without creating a new clinical
contradiction. In particular verify:

1. exactly one primary indication subtype, with subtype 2 precedence for clear
   study-period treatment and a single cm_indication handoff;
2. role missing -> not_evaluable, while boundary requires at least two sourced
   plausible interpretations; not_evaluable dominates a blocking gap;
3. blank/vague/non-mappable indication remains a visible coverage gap, not a
   fabricated "no indication" positive;
4. all six Chinese labels exist; PD wording is verify-only;
5. priority comes from a versioned rule/policy and does not turn
   not_evaluable into an "unknown risk";
6. upper-category matching follows the target granularity; the absence-event
   journey marker anchors to the CM interval; cross-domain evidence may group
   related risks but must not silently merge distinct domain identities;
7. challenge cases 19-30 are medically coherent and sufficient for this slice.

For any remaining gap cite the exact current clause, give a synthetic
counterexample, severity, replacement wording, and a deterministic test. Return
the original six-section conference schema and end with exactly one verdict:
`ACCEPT`, `ACCEPT_WITH_GAPS`, or `VETO`. Keep evidence, inference,
recommendation, and uncertainty separate. Codex remains final authority.
